Dyne Therapeutics(DYN) Newsfilter·2025-02-14 21:05Core Insights - Dyne Therapeutics will present data from two clinical trials at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference, focusing on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) [1][5] Group 1: Presentations - The company will have two oral presentations: one on the DELIVER trial for DYNE-251 in DMD and another on the ACHIEVE trial for DYNE-101 in DM1 [2][5] - The DELIVER trial presentation will cover safety and efficacy data for males with DMD mutations amenable to exon 51 skipping [2] - The ACHIEVE trial presentation will focus on safety and efficacy data in adults with DM1 [2] Group 2: Poster Sessions - Poster presentations will occur from March 16 to March 18, featuring various studies related to neuromuscular diseases [3][8] - Topics include real-world data on myotonic dystrophy type 1 and the FORCE™ platform's impact on muscle function in facioscapulohumeral muscular dystrophy [8] Group 3: Symposium - A symposium titled "Harnessing the FORCE™ Platform to Advance Targeted Therapies for Neuromuscular Diseases" will take place on March 18, detailing the platform's capabilities and data from the lead clinical programs [5][7] Group 4: Company Overview - Dyne Therapeutics is dedicated to developing innovative therapeutics for genetically driven neuromuscular diseases, utilizing its FORCE™ platform to target muscle and the central nervous system [6]